Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Reducing opioid medication during pregnancy may not ease neonatal opioid withdrawal syndrome (opens in a new tab)

news-medical.net · 2026-10-30

Short answerEvidenceSource

Short answer

Not supported

Not supported.

2 claims go further than the study. 4 other points were not covered by the paper.

  • 2 overstated
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

Two of six claims overstate the study. Four claims the study doesn't address.

  • 2 overstated
  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedPregnant patients receiving medication to treat opioid use disorder should not reduce their medication dose out of fear that it will worsen withdrawal symptoms in their newborns, according to a new study led by researchers at the University of Maryland School of Medicine.View evidenceHide evidence

Why this verdict

The supplied profile supports only that this was an observational cohort evaluating associations involving maternal MOUD dose, umbilical cord tissue drug levels, and NOWS severity. The lead claim turns this into a clinical/causal recommendation that patients should not reduce dose because dose will not worsen newborn withdrawal. Even if the underlying no-association finding were present, this causal-strength recommendation would outrun an observational association study; at abstract depth, the actual no-association result is also not reported.

1

Study evidence

Cohort study that evaluates whether methadone and buprenorphine concentrations measured in umbilical cord tissue are associated with maternal medication for opioid use disorder (MOUD) dose.

“This cohort study evaluates associations of methadone and buprenorphine levels in umbilical cord tissue with medication for opioid use disorder dosage”
2

Study evidence

Observational cohort study evaluating whether umbilical cord tissue concentrations of methadone and buprenorphine are associated with neonatal opioid withdrawal syndrome (NOWS) severity, and examining relationships with medication for opioid use disorder (MOUD) dosage.

“Umbilical Cord Methadone and Buprenorphine Levels and Neonatal Opioid Withdrawal Severity”
Claim 2 of 6OverstatedThe findings suggest that lowering medication doses during pregnancy is not an effective strategy for preventing severe neonatal opioid withdrawal syndrome (NOWS) and reinforce the importance of maintaining treatment to protect mothers from relapse and overdose.View evidenceHide evidence

Why this verdict

The profile does not provide results showing that lowering doses is ineffective for preventing severe NOWS, and the study design is observational rather than an intervention or effectiveness study. The additional assertion about maintaining treatment to protect mothers from relapse and overdose concerns maternal outcomes not described as evaluated in the supplied paper profile.

1

Study evidence

Cohort study that evaluates whether methadone and buprenorphine concentrations measured in umbilical cord tissue are associated with maternal medication for opioid use disorder (MOUD) dose.

“This cohort study evaluates associations of methadone and buprenorphine levels in umbilical cord tissue with medication for opioid use disorder dosage”
2

Study evidence

Observational cohort study evaluating whether umbilical cord tissue concentrations of methadone and buprenorphine are associated with neonatal opioid withdrawal syndrome (NOWS) severity, and examining relationships with medication for opioid use disorder (MOUD) dosage.

“Umbilical Cord Methadone and Buprenorphine Levels and Neonatal Opioid Withdrawal Severity”
Claim 3 of 6Not coveredThe research letter, published in JAMA Network Open, examined whether doses of methadone and buprenorphine during pregnancy were associated with the severity of neonatal opioid withdrawal syndrome in newborns.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the study evaluated associations of cord tissue methadone/buprenorphine levels with maternal MOUD dosage and with NOWS severity. It does not clearly establish, at this depth, that maternal medication dose itself was directly examined for association with NOWS severity, nor does the supplied profile verify the journal publication detail.

1

Study evidence

Cohort study that evaluates whether methadone and buprenorphine concentrations measured in umbilical cord tissue are associated with maternal medication for opioid use disorder (MOUD) dose.

“This cohort study evaluates associations of methadone and buprenorphine levels in umbilical cord tissue with medication for opioid use disorder dosage”
2

Study evidence

Observational cohort study evaluating whether umbilical cord tissue concentrations of methadone and buprenorphine are associated with neonatal opioid withdrawal syndrome (NOWS) severity, and examining relationships with medication for opioid use disorder (MOUD) dosage.

“Umbilical Cord Methadone and Buprenorphine Levels and Neonatal Opioid Withdrawal Severity”
Claim 4 of 6Not coveredThe study found that levels of methadone and buprenorphine measured in umbilical cord tissue after childbirth were not associated with the severity of withdrawal syndrome.View evidenceHide evidence

Why this verdict

The profile supports that the study evaluated whether umbilical cord tissue drug concentrations were associated with NOWS severity, but the abstract profile does not report the results, direction, magnitude, or statistical significance. Therefore the stated finding of no association cannot be verified at abstract depth.

1

Study evidence

Observational cohort study evaluating whether umbilical cord tissue concentrations of methadone and buprenorphine are associated with neonatal opioid withdrawal syndrome (NOWS) severity, and examining relationships with medication for opioid use disorder (MOUD) dosage.

“Umbilical Cord Methadone and Buprenorphine Levels and Neonatal Opioid Withdrawal Severity”
Claim 5 of 6Not coveredThe study analyzed 92 pregnancies involving patients who received methadone or buprenorphine for at least 30 days before delivery, and severe withdrawal occurred in approximately 44 percent of the newborns.View evidenceHide evidence

As statedapproximately 44 percent

Why this verdict

The supplied abstract profile does not provide the sample size, cohort inclusion criterion of at least 30 days of treatment before delivery, or the approximately 44% severe withdrawal figure. Those numerical and eligibility details cannot be verified from the abstract-level evidence supplied.

1

Study evidence

Cohort study that evaluates whether methadone and buprenorphine concentrations measured in umbilical cord tissue are associated with maternal medication for opioid use disorder (MOUD) dose.

“This cohort study evaluates associations of methadone and buprenorphine levels in umbilical cord tissue with medication for opioid use disorder dosage”
2

Study evidence

Observational cohort study evaluating whether umbilical cord tissue concentrations of methadone and buprenorphine are associated with neonatal opioid withdrawal syndrome (NOWS) severity, and examining relationships with medication for opioid use disorder (MOUD) dosage.

“Umbilical Cord Methadone and Buprenorphine Levels and Neonatal Opioid Withdrawal Severity”
Claim 6 of 6Not coveredThe authors said the study's small sample size and limited racial and ethnic diversity are important limitations, and the findings do not eliminate the need for appropriate monitoring and care for exposed newborns.View evidenceHide evidence

Why this verdict

The supplied profile lists abstract-depth limitations such as missing sample size, missing methods, missing covariate details, and limited causal inference from the observational design. It does not verify that the authors identified small sample size or limited racial/ethnic diversity as limitations, nor does it verify the stated monitoring-and-care caveat.

1

Study evidence

Cohort study that evaluates whether methadone and buprenorphine concentrations measured in umbilical cord tissue are associated with maternal medication for opioid use disorder (MOUD) dose.

“This cohort study evaluates associations of methadone and buprenorphine levels in umbilical cord tissue with medication for opioid use disorder dosage”
2

Study evidence

Observational cohort study evaluating whether umbilical cord tissue concentrations of methadone and buprenorphine are associated with neonatal opioid withdrawal syndrome (NOWS) severity, and examining relationships with medication for opioid use disorder (MOUD) dosage.

“Umbilical Cord Methadone and Buprenorphine Levels and Neonatal Opioid Withdrawal Severity”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper evaluates whether maternal MOUD dosage is associated with methadone and buprenorphine concentrations measured in umbilical cord tissue.

    The story focuses on dose or cord levels as predictors of NOWS severity. It does not clearly reflect the dose-to-cord-concentration association as a distinct paper aim or contribution.

    From cohort study; observational cohort

  • At abstract depth, the profile does not provide specific results, effect estimates, statistical significance, or direction of the reported associations.

    The story reports definitive no-association findings, but the supplied abstract-level profile says those result details are not available in the excerpt.

    From cohort study; cohort study; observational cohort

  • At abstract depth, the profile does not provide sample size, NOWS severity definition or scale, timing of assessments, covariates, or model specification.

    The story supplies sample size and severity prevalence and mentions different limitations, but these details are not verifiable from the supplied paper profile. The profile’s missing-methods limitations are not reflected.

    From cohort study; cohort study

  • The profile frames cord tissue concentrations partly as a potential biomarker or exposure metric for perinatal MOUD exposure research/monitoring.

    The story mentions cord tissue measurement but does not convey the secondary biomarker-characterization element or the associated lack of validation details noted in the profile.

    From observational cohort

1 thing the story did carry across
  • The paper evaluates whether umbilical cord tissue methadone and buprenorphine concentrations are associated with NOWS severity.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEvaluate whether umbilical cord methadone and buprenorphine concentrations are associated with neonatal opioid withdrawal syndrome (NOWS) severity.cohort studyExpand

In plain English

Observational cohort study evaluating whether umbilical cord tissue concentrations of methadone and buprenorphine are associated with neonatal opioid withdrawal syndrome (NOWS) severity, and examining relationships with medication for opioid use disorder (MOUD) dosage.

Key findings

No separate finding listed.

“Umbilical Cord Methadone and Buprenorphine Levels and Neonatal Opioid Withdrawal Severity”
What this piece can’t prove
  • Provided excerpt is the title and a one-sentence abstract objective only; no results, sample size, NOWS severity definition/scale, timing of assessments, covariates, or specific statistical methods are reported in the available text.
2secondary dataEvaluate whether methadone and buprenorphine concentrations measured in umbilical cord tissue are associated with maternal MOUD (methadone/buprenorphine) dosage.cohort studyExpand

In plain English

Cohort study that evaluates whether methadone and buprenorphine concentrations measured in umbilical cord tissue are associated with maternal medication for opioid use disorder (MOUD) dose.

Key findings

No separate finding listed.

“This cohort study evaluates associations of methadone and buprenorphine levels in umbilical cord tissue with medication for opioid use disorder dosage”
What this piece can’t prove
  • Abstract does not provide sample size, numerical effect estimates, measures of association, statistical significance, or details on covariate adjustment.
  • Methods and analytic details (assay methods, timing of dose measurement, covariates, and model specification) are not reported in the supplied abstract excerpt.
3secondary dataCharacterize/validate the relationship between maternal MOUD exposure (type/dose) and umbilical cord tissue drug levels as a potential exposure biomarker for perinatal opioid exposure research/monitoring.observational cohortExpand

In plain English

Cohort study that measured methadone and buprenorphine concentrations in umbilical cord tissue and evaluated their associations with maternal medication for opioid use disorder (MOUD) dosing and with neonatal opioid withdrawal syndrome severity, framed as characterization of cord-tissue drug levels as a potential exposure biomarker.

Key findings

  • The study evaluated associations between umbilical cord concentrations of methadone and buprenorphine and maternal MOUD dose, and between cord concentrations and neonatal opioid withdrawal severity.
“...associations of methadone and buprenorphine levels in umbilical cord tissue with medication for opioid use disorder dosage”
What this piece can’t prove
  • Observational cohort design (as reported) limits causal inference between maternal dose, cord concentrations, and neonatal outcomes.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

In pregnant patients receiving treatment for opioid use disorder, does methadone reduce rates of neonatal opioid withdrawal syndrome compared to buprenorphine?

Evidence-Based Practice · 2024 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.